Karuna parts ways with executive as it gears up for schizophrenia drug's high-profile launch

Karuna Therapeutics is gearing up for a potential launch of schizophrenia med KarXT—one analysts say could be “amongst the highest in profile in recent times.” But it’ll now be doing it without its Chief Commercial Officer Charmaine Lykins, who quietly departed Thursday afternoon.